ライフサイエンスコーパス: smokeless

1 they have been marketed as a cheaper, safer smokeless alternative to traditional cigarettes and a po

2 l prevalence of current tobacco use (smoked, smokeless, and any tobacco use) among 6729 HIV-positive

3 rs, such as alcohol and tobacco (smoking and smokeless), but dietary factors and the existence of gen

4 The smokeless cigarette, Eclipse, has comparable ROS with ci

5 , respectively), followed by smoky coal, and smokeless coal (GM:148 and 115 mug/m(3), respectively).

6 6 times higher when burning smoky coal than smokeless coal and varied by up to a factor of 3 between

7 or users of smoky coal, compared to users of smokeless coal and wood.

8 ed the highest pollutant levels, followed by smokeless coal, kiln-dried wood, and seasoned wood.

9 nwei and Fuyuan females who used smoky coal, smokeless coal, or wood and 10 local controls who used e

10 in health evaluations is usually compared to smokeless coal--an anthracite coal available in some par

11 ates (GMR = 0.43), compared to areas burning smokeless coal.

12 solid sorbent traps from the headspace of a smokeless gunpowder sample.

13 Smokeless oral nicotine products are addictive, and thei

14 The market of smokeless oral nicotine products has transformed since t

15 -containing products, whether combustible or smokeless, pose a growing threat to cardiovascular (CV)

16 itive, and rapid method for the detection of smokeless powder components, from five different types o

17 ts resulted in perfect classification of the smokeless powder with respect to manufacturer.

18 ESI FTICR mass spectrometry of smokeless powder, TNT, and Powermite resolves and identi

19 rotoluene (TNT), and low explosives (several smokeless powders) resulting in the detection of 26-35 n

20 filtered cigar, cigarillo, pipe, hookah, and smokeless products); disability types (mobility, self-ca

21 31-2.59], respectively), attempt to purchase smokeless tobacco (adjusted OR, 2.16 [95% CI, 1.90-2.45]

22 rrent prevalence, 15.7% vs 3.9%; P<.001) and smokeless tobacco (current prevalence, 8.7% vs 0.4%; P<.

23 Framework Convention on Tobacco Control for smokeless tobacco (eg, spitting bans).

24 s to determine whether an aqueous extract of smokeless tobacco (moist snuff) increases clearance of m

25 the validity of self-reported information on smokeless tobacco (SLT) use is uncertain.

26 s successfully applied to the analysis of 15 smokeless tobacco (SLT) users and 15 non-users of tobacc

27 on (EU) legislation bans the sale of snus, a smokeless tobacco (SLT) which is considerably less harmf

28 Despite the reported effects of smokeless tobacco (ST) on the periodontium and high prev

29 mucosal lesions frequently occur at sites of smokeless tobacco (ST) placement.

30 ties have implemented a comprehensive ban on smokeless tobacco advertisement, promotion, and sponsors

31 must incorporate further measures to reduce smokeless tobacco and areca nut consumption in populatio

32 consumption, and could be prevented through smokeless tobacco and areca nut control.

33 favoured by most smokers (82%) overall, but smokeless tobacco and bidis were commonly used in India

34 Furthermore, combined use of smokeless tobacco and cigarettes did not increase overal

35 cancer mortality rate among combined users (smokeless tobacco and cigarettes), based on the rates fo

36 al. describe the association between use of smokeless tobacco and head and neck cancer in 11 US case

37 Few or no associations between each type of smokeless tobacco and HNC were observed among ever cigar

38 tically review policies that are relevant to smokeless tobacco and its context and investigate their

39 e exposed organotypic cultures for 3 days to smokeless tobacco aqueous extracts and determined the ch

40 The FDA thus concluded that cigarettes and smokeless tobacco are subject to FDA jurisdiction becaus

41 Current use of smokeless tobacco at baseline was associated with 1.27-f

42 correlated with number of tins or pouches of smokeless tobacco consumed.

43 Many countries have implemented smokeless tobacco control policies, including those that

44 e extent of the policy implementation gap in smokeless tobacco control, discuss key reasons on why it

45 For smokeless tobacco control, many countries have adopted p

46 We hypothesized that smokeless tobacco could modulate the growth of keratinoc

47 A determined that nicotine in cigarettes and smokeless tobacco does "affect the structure or any func

48 Overall, these data suggest that smokeless tobacco elicits plasma exudation in the oral m

49 lth questionnaire revealed that he was using smokeless tobacco every day.

50 associations were observed between snus and smokeless tobacco excluding snus and incidence of oral h

51 effects of cigarette smoke extract (CSE) and smokeless tobacco extract (STE) on cell survival and mot

52 Exposure to smokeless tobacco extract was associated with a signific

53 Smokeless tobacco extract-induced leaky site formation a

54 Indomethacin had no significant effects on smokeless tobacco extract-induced responses.

55 th Whole Smoke-Conditioned Medium (WS-CM) or Smokeless Tobacco Extracts (STE), and stimulated with li

56 , therefore, were differentially affected by smokeless tobacco extracts in an organotypic tissue mode

57 In contrast, smokeless tobacco extracts promoted fibroblast growth at

58 shown that most consumers use cigarettes and smokeless tobacco for pharmacological purposes, includin

59 Similarly, smokeless tobacco has the potential to increase the risk

60 Use of smokeless tobacco in the United States has been relative

61 eless tobacco, only 138 (77%) Parties define smokeless tobacco in their statutes.

62 d of accelerating the decline in smoking and smokeless tobacco initiation.

63 dical school curricula, specific training in smokeless tobacco intervention, tobacco intervention tra

64 Smokeless tobacco is a powerful autonomic and hemodynami

65 Smokeless tobacco is associated with pathologic alterati

66 Use of smokeless tobacco is becoming a global cause of concern,

67 Smokeless tobacco is consumed by 356 million people glob

68 Although awareness of the harms related to smokeless tobacco is growing in many parts of the world,

69 factor for periodontal disease, the role of smokeless tobacco is unclear.

70 The presence of oral smokeless tobacco lesions among adolescents may be an ea

71 Preventing smokeless tobacco lesions and their possible malignant t

72 Smokeless tobacco lesions were detected in 1.5% of stude

73 tronger risk factor than chewing tobacco for smokeless tobacco lesions, but the use of either of thes

74 cohol or cigarettes may increase the risk of smokeless tobacco lesions.

75 These results indicate that smokeless tobacco may also be an important risk factor f

76 te the burden of oral cancer attributable to smokeless tobacco or areca nut consumption globally and

77 ancer diagnosed in 2022 were attributable to smokeless tobacco or areca nut consumption, accounting f

78 of oral cancer globally are attributable to smokeless tobacco or areca nut consumption, and could be

79 day database to obtain cases attributable to smokeless tobacco or areca nut consumption.

80 Consuming products that contain smokeless tobacco or areca nut increases the risk of ora

81 reca nut consumption globally and by type of smokeless tobacco or areca nut product in four major con

82 ns (PAFs) using prevalence of current use of smokeless tobacco or areca nut products from national su

83 ctively) mortality compared with never using smokeless tobacco or cigarettes.

84 and key south Asian languages, to summarise smokeless tobacco policies and their impact.

85 eligible studies were included as describing smokeless tobacco policies.

86 ed since the last American Heart Association smokeless tobacco policy statement.

87 itiatives were associated with reductions in smokeless tobacco prevalence of between 4.4% and 30.3% f

88 Outcomes for impact assessment included smokeless tobacco prevalence, uptake, cessation, and hea

89 Shammah is a smokeless tobacco product often mixed with lime, ash, bl

90 arction (MI) in people who use snus, a moist smokeless tobacco product, we hypothesized that disconti

91 Smokeless tobacco products (STPs) are widely used in cer

92 tobacco users are advised to quit the use of smokeless tobacco products compared to tobacco users.

93 A plethora of smokeless tobacco products lead to unacceptable exposure

94 han five cigarettes, bidis, a water pipe, or smokeless tobacco products since the quit date), confirm

95 s, six (3%) measure content and emissions of smokeless tobacco products, and 41 (23%) mandate pictori

96 Only 34 (19%) Parties tax or report taxing smokeless tobacco products, six (3%) measure content and

97 Its use via smokeless tobacco products, some of which contain saccha

98 with regular and heavy nicotine intake from smokeless tobacco rather than from smoking.

99 n smokeless tobacco users that mentioned any smokeless tobacco relevant policies since 2005, except s

100 ales bans reported significant reductions in smokeless tobacco sale (6.4%) and use (combined sex 17.6

101 Current users of smokeless tobacco should be informed of its harm and adv

102 A) asserted jurisdiction over cigarettes and smokeless tobacco under the Federal Food, Drug, and Cosm

103 co smoking (1.90 [1.38-2.62]; p<0.0001), and smokeless tobacco use (1.32 [1.03-1.69]; p=0.030) than i

104 ment for confounders, no association between smokeless tobacco use and all-cause (hazard ratio = 1.1,

105 ter understand the cancer risks of exclusive smokeless tobacco use and dual use of smokeless tobacco

106 Both smoked and smokeless tobacco use and frequency of use vary widely a

107 Previous studies on smokeless tobacco use and head and neck cancer (HNC) hav

108 rvey was to evaluate the association between smokeless tobacco use and severe active periodontal dise

109 udy was to characterize the relation between smokeless tobacco use and the risk of all-cause and dise

110 Smokeless tobacco use appears to be associated with HNC,

111 Sole and exclusive smokeless tobacco use demonstrated associations with tot

112 e smoking, nicotine replacement therapy, and smokeless tobacco use during pregnancy are associated wi

113 d with significantly higher smoking and male smokeless tobacco use in most Appalachian disparity stat

114 The pooled prevalence of current smokeless tobacco use in pregnant women was lowest in th

115 udy, however, reported an increased trend in smokeless tobacco use in the youth after a total sales b

116 The health effects of smokeless tobacco use need further documentation.

117 The difference in smokeless tobacco use prevalence between HIV-positive an

118 Framework Convention on Tobacco Control) on smokeless tobacco use remains unclear.

119 However, global efforts to control smokeless tobacco use trail behind the progress made in

120 orld, few Parties collect or present data on smokeless tobacco use under global or national surveilla

121 Exclusive smokeless tobacco use was associated with greater odds o

122 (externalizing problems predicted cigar and smokeless tobacco use).

123 7.8) for tobacco smoking, 3.4% (1.8-5.6) for smokeless tobacco use, and 27.1% (22.8-31.7) for any tob

124 1.9) for tobacco smoking, 2.1% (1.1-3.4) for smokeless tobacco use, and 3.6% (95% CI 2.3-5.2) for any

125 ative prevalence ratios for tobacco smoking, smokeless tobacco use, and any tobacco use separately fo

126 level, country income level, smoking status, smokeless tobacco use, and exposure to dental education

127 luc), in urine and plasma after cessation of smokeless tobacco use, in which NNK is administered p.o.

128 e weak) and reported mainly on prevalence of smokeless tobacco use.

129 Similar associations were noted for pipe and smokeless tobacco use.

130 are associated with meaningful reductions in smokeless tobacco use.

131 its context and investigate their impact on smokeless tobacco use.

132 d at intervals 2-126 days after cessation of smokeless tobacco use.

133 lity of borderline significance among female smokeless tobacco users (hazard ratio = 1.7, 95% CI: 1.0

134 eline (1971-1975) were categorized as either smokeless tobacco users (n = 1,068) or non-smokeless tob

135 r smokeless tobacco users (n = 1,068) or non-smokeless tobacco users (n = 5,737).

136 igarettes), based on the rates for exclusive smokeless tobacco users and exclusive smokers, was highe

137 The exposure of smokeless tobacco users and smokers to carcinogens and t

138 ays after cessation than at baseline in both smokeless tobacco users and smokers, indicating stereose

139 Gluc (26.1 +/- 15.1 versus 39.6 +/- 26.0) in smokeless tobacco users and smokers.

140 Globally, a smaller proportion of smokeless tobacco users are advised to quit the use of s

141 Cigarette and smokeless tobacco users had more diverse oral bacterial

142 3.89 +/- 2.43) were significantly shorter in smokeless tobacco users than in smokers.

143 lusion criteria were all types of studies on smokeless tobacco users that mentioned any smokeless tob

144 The mortality experience of smokeless tobacco users was not significantly greater th

145 ized the oral microbiome of cigarette users, smokeless tobacco users, and non-users over 4 months (fo

146 ants were current cigarette, cigar, pipe, or smokeless tobacco users, respectively.

147 assessed the 20-year mortality experience of smokeless tobacco users.

148 The user prevalence of smokeless tobacco was 7.7% (7.5% to 8.0%) and prevalence

149 Current use of smokeless tobacco was associated with coronary heart dis

150 the authors examined whether current use of smokeless tobacco was associated with increased incidenc

151 In conclusion, current use of smokeless tobacco was associated with increased risk of

152 Past use of smokeless tobacco was not associated with CVD incidence.

153 adults and never-smokers who currently used smokeless tobacco were twice as likely to have severe ac

154 lusive smokeless tobacco use and dual use of smokeless tobacco with other tobacco products, including

155 cigarette tobacco products (cigar, pipe, and smokeless tobacco) remain unclear, yet such data are req

156 oncigarette products (eg, cigars, pipes, and smokeless tobacco), which have been understudied because

157 ettes, cigarettes, and other (cigar, hookah, smokeless tobacco).

158 , living in a rural area, smoking, consuming smokeless tobacco, and being underweight and the distric

159 use of various tobacco products [cigarettes, smokeless tobacco, and electronic nicotine delivery syst

160 ion on bidis (small hand-rolled cigarettes), smokeless tobacco, and locally brewed alcohols.

161 0.05) among sole users of cigars, pipes, and smokeless tobacco, compared with their respective refere

162 s, pipe tobacco, hookah, snus pouches, other smokeless tobacco, dissolvable tobacco, bidis, and krete

163 ttes, ENDS, cigars, pipes, hookah, snus, and smokeless tobacco, excluding snus at W1 to W4.

164 including e-cigarettes, cigarettes, cigars, smokeless tobacco, hookah, pipes, and nicotine replaceme

165 57 countries had policies targeting smokeless tobacco, of which 17 had policies outside the

166 approach to control the demand and supply of smokeless tobacco, only 138 (77%) Parties define smokele

167 isease (PAD), but it remains unknown whether smokeless tobacco, such as Swedish snuff (snus), is also

168 Smokeless tobacco, used by more than 300 million people

169 r pipe smokers, and 2% were current users of smokeless tobacco.

170 95% CI, 1.03-1.39) compared with never using smokeless tobacco.

171 for pipes, and 1410 participants (2.1%) for smokeless tobacco.

172 ducts: cigarettes, e-cigarettes, cigars, and smokeless tobacco.

173 sues, less is understood about the effect of smokeless tobacco.

174 te smoke may have more profound effects than smokeless tobacco.

175 f quitting which do not include switching to smokeless tobacco.

176 e acute hemodynamic and autonomic effects of smokeless tobacco.

177 cigarette/cigar use (302 [3.2%]), and stable smokeless tobacco/cigarette use (141 [1.6%]).

178 erging alternative tobacco products, such as smokeless tobacco/snus, hookah and water pipes, e-cigare

179 All smokeless tobaccos stimulated keratinocyte proliferation

180 revalence of current tobacco use (smoked and smokeless) was estimated for every country.